Financial Highlights for the Six Months Ended

Financial Highlights for the Six Months Ended

Revenue decreased by 9% year-over-year to $29.2

million for the six months ended March 31, 2023 from $32.1 million for the same period of the prior fiscal year. The revenue demoninated

in Renminbi ("RMB") decreased by 1 million RMB (equvalent to $0.14 million U.S. dollars ("USD"), using the average

conversion rate for current period) The decrease in revenue translated in USD is primarily attributable to the depreciation of RMB against

USD from an average exchange rate of 1 USD = 6.3712 RMB for the six months ended March 31, 2022 to an average exchange rate of 1 USD =

6.9761 for the six months ended March 31, 2023.

Gross profit decreased by 34% to $2.3 million

for the six months ended March 31, 2023 from $3.5 million for the same period of the prior fiscal year. Gross margins were 7.9% and 10.9%

for the six months ended March 31, 2023 and 2022, respectively. The decreased gross profit was mainly due to decreased gross margin from

heparin products, the sales per unit of which has decreased compared to that in the six months ended March 31, 2022.

Income from operations was $0.2 million for the

six months ended March 31, 2023, compared to income from operations of $1.2 million for the same period of the prior fiscal year, due

to the decrease of gross profit, offset by the decreased of selling, general and administrative expense of $0.2 million.

Net income was $0.4 million for the six

months ended March 31, 2023, compared to the net income of $0.2 million for the same period of the prior fiscal year. The increase

was mainly due to the $1.2 million increase in investment income from the change of fair value of marketable securities, offset the

$1.0 million decrease in income from operations as described above.

Net income attributable to Qilian

International was $0.5 million or earnings per share of $0.01 for the six months ended March 31, 2023, compared to net income

attributable to Qilian International of less than $0.1 million or, or earnings per share of $0.00, for the same period of the

prior fiscal year. Subsidiaries with non controlling interest owners incurred loss for the six months ended March 31, 2023

compared to income for the same period in the prior year.

Unaudited Financial Results for the Six months

ended March 31, 2023

For the six months ended March 31, 2023, revenue

decreased by $2.9 million, or 9%, to $29.2 million from $32.1 million for the same period of the prior fiscal year.

For the six months ended March 31, 2023, revenue

from heparin products decreased by $0.4 million or 4%. The sales price of heparin product decreased from RMB 42.8 per gram for the six

month ended March 31, 2022 to RMB 38.8 per gram for the six month ended March 31, 2023. Commence from February 2023, heparin product became

one of the centralized procurement medicine by the PRC government which intensified the competition of the product in the market.

For the six months ended March 31, 2023, revenue

from oxytetracycline & licorice products increased by $0.3 million or 1.7%. This is a normal fluctuation in our oxytetracycline &

licorice products line business and increased sales only accounts for less than 1% of our total sales which is related to slight sales quantity

increase in the current period.

Cost of revenue decreased by $1.7 million, or

6%, to $26.9 million for the six months ended March 31, 2023 from $28.6 million for the same period of the prior fiscal year. The decrease

in cost of sales is primarily attributable to the depreciation RMB against USD, from an average exchange rate of 1 USD = 6.3712 RMB for

the six months ended March 31, 2022 to an average exchange rate of 1 USD = 6.9761 for the six months ended March 31, 2023. The cost of

revenue denominated in RMB increased by 5.3 million RMB which is discussed in the section "Gross profit" below.

Gross profit decreased by $1.2 million, or

34%, to $2.3 million for the six months ended March 31, 2023 from $3.5 million for the same period of the prior fiscal year, mainly

due to the decrease of gross margin of $0.9 million from heparin product and susage casing, $0.5 million from oxytetracycline &

Licorice products, partially offset by the increased gross margin of $0.2 million from natural fertilizer. As a result, gross margin

percentage decreased to 7.9% for the six months ended March 31, 2023 from 10.9% for the same period of the prior fiscal year.

Gross profit margin for oxytetracycline &

Licorice products decreased by 1.8% for the six months ended March 31, 2023 as a result of the increase production cost due to the higher

labor cost and utility cost post pandemic, compared to the same period of last year. Gross profit margin for heparin product and susage

casing decreased by 6.5% for the six months ended March 31, 2023 as a result of the decreased selling price for heparin product in the

current period, compared to the same period of prior year, due to intense price competition of the product in the market, as Chinese government

announced centralized procurement of the medicine from beginning of 2023.

Gross profit margin for fertilizer increased by

29% as the Company became one of designated suppliers by Gansu government to provide organic fertilizer for certain soil improvement projects.

The sales associated with these projects are $0.3 million, with a gross profit margin over 50%.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were $2.1 million for

the six months ended March 31, 2023, representing an decrease of approximately $0.2 million, or 9%, from $2.3 million for six months ended

March 31, 2022. The decrease was mainly attributable $0.4 million decrease of research and development expense related to developing new

products in the oxytetracycline & licorice products line for six months ended March 31, 2022, offset by increase of salary and incentive

bonus for our sales force for their post-pandemic sales effort for the six months ended March 31, 2023.

Investment income (loss)

Investment income was $0.2 million for the six

months ended March 31, 2023, compared to investment loss of $1.0 million for the same period of the prior fiscal year. Investment income

(loss) is driven by the fair value change of the investment in available-for-sale securities.

Net income and net income attributable to Qilian

Net income was approximately $0.4 million

and $0.2 million for the six months ended March 31, 2023 and 2022. After deducting non-controlling interests, net income

attributable to Qilian International was approximately $0.5 million for the six months ended March 31, 2023, compared to net income

attributable to Qilian International of less than $0.1 million for the same period of the prior fiscal year.

Earnings per share-basic and diluted

After deducting non-controlling interests, earnings

per share attributable to the Company was $ 0.01 per basic and diluted share, for the six months ended March 31, 2023, compared to earnings

per share of less than $0.01 per basic and diluted share, for the same period of the prior fiscal year.

Weighted average number of shares outstanding

was 35,750,000 for the six months ended March 31, 2023, compared to 35,750,000 for the same period of last fiscal year.

As of March 31, 2023, the Company had cash and

cash equivalent of $8.9 million, compared to $14.3 million as of September 30, 2022. Total working capital was $17.9 million as of March

31, 2023, compared to $20.9 million as of September 30, 2022.

Net cash used in operating activities was $0.4 million for the six

months ended March 31, 2023, compared to net cash provided by operating activities of $4.2 million for the same period last year. Cash

flows from the adjustment made to reconcile net income to net cash provided by (used in) operating actitities decreased by $0.9 million

mainly due to the increased unrealized investment gain from marketable securities of $1.2 million. The decrease of cash provided by operating

activities was also due to a decrease of $3.9 million in cash inflows from the change in working capital, primarily driven by $1.5 million

of increase in cash outflow due to increase in inventory, $1.3 million decrease in cash inflow due to increase in note receivable, $1.6

million decrease in cash inflow due to decrease in note payable, $2.2 million decrease in cash inflow due to increase in account receivable,

offset by $1.2 million increase of cash inflow from the decrease of other current assets, $0.8 million decrease of cash outflow from the

increase of account payable, and $1.1 million of increase in cash inflow due to the increase in advance from customers.

cash used in investing activities was $2.3 million for the six months ended March 31, 2023, compared to net cash used in investing activities

$3.5 million for the same period last year. Cash used in investing activities for the six months ended March 31, 2023 includes

cash used for purchase of property and equipment of $0.4 million, cash used for purchase of intangible assets of $1.9 million and cash

used for purchase of non controlling interest less than $0.1 million. Cash used in investing activities for the six months ended March

31, 2022 includes cash used for purchase of property and equipment of $1.8 million and cash used for purchase of intangible assets of

Net cash used in financing activities was $2.9

million for the six months ended March 31, 2023, compared to net cash provided by financing activities $3.1 million for the same period

of last year. Cash used in financing activities for the six months ended March 31, 2023 includes cash used for repayment of

bank loan and bank notes payable of $1.0 million, as well as dividend paid of $1.8 million. Cash provided by financing activities for

the six months ended March 31, 2022 include cash proceeds from bank loans of $3.1 million.

About Qilian International Holding Group Limited

Qilian International Holding Group Limited, headquartered